Schrodinger (Schrodinger) Debt-to-Asset : 0.16 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Schrodinger Debt-to-Asset?

Schrodinger's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $16.9 Mil. Schrodinger's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $111.0 Mil. Schrodinger's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $803.0 Mil. Schrodinger's debt to asset for the quarter that ended in Dec. 2023 was 0.16.

Schrodinger Debt-to-Asset Historical Data

The historical data trend for Schrodinger's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schrodinger Debt-to-Asset Chart

Schrodinger Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.09

0.02

0.11

0.17

0.16

Schrodinger Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.17	0.14	0.14	0.16	0.16

Competitive Comparison of Schrodinger's Debt-to-Asset

For the Health Information Services subindustry, Schrodinger's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Schrodinger's Debt-to-Asset Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Schrodinger's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Schrodinger's Debt-to-Asset falls into.

Schrodinger Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Schrodinger's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(16.868	+	111.014)	/	802.955
	=	0.16

Schrodinger's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(16.868	+	111.014)	/	802.955
	=	0.16

Schrodinger (NAS:SDGR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Schrodinger Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Schrodinger's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Schrodinger (Schrodinger) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Schrodinger Inc (NAS:SDGR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

43Z:Germany

Address

1540 Broadway, 24th Floor, New York, NY, USA, 10036

Website

https://www.schrodinger.com

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Executives

Kenneth Patrick Lorton	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Margaret Dugan	officer: Chief Medical Officer	C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Yvonne Tran	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Nancy Thornberry	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Ramy Farid	director, 10 percent owner, officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Geoffrey Craig Porges	officer: EVP & CFO	1540 BROADWAY, 24TH FL., NEW YORK NY 10036
Arun Oberoi	director	100 EAST DAVIE STREET, RALEIGH NC 27601
Robert Lorne Abel	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Karen Akinsanya	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Joel Lebowitz	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
David E Shaw	10 percent owner	120 WEST FORTY-FIFTH STREET, 39TH FLOOR, NEW YORK NY 10036
Jorg Weiser	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Jennifer Daniel	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
D'cruz Cony	officer: See Remarks	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Richard Friesner	director, 10 percent owner	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036